Broad Institute in the driver’s seat following PTAB’s favorable ruling

The Patent Trial and Appeal Board (PTAB) has ruled in favor of the Broad Institute of MIT and Harvard in its dispute with the University of California (UC) Berkeley and the University of Vienna over intellectual property issues surrounding CRISPR/Cas9 technology. The powerful technology can be used to edit and modify the genome of organisms.

Icon steps up for patient-reported outcome measure endpoint validation

The FDA has chosen Icon to create industry-standard patient-reported outcome (PRO) measures and to validate those endpoints for antibacterial drug trials. Partnering on the initiative with Icon is the Biomarkers Consortium and the Foundation of the National Institutes of Health (FNIH). Also involved is the Infectious Diseases Society of America and the National Institute of Allergy and Infectious Diseases.

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.